American Journal of Kidney Diseases
Volume 52, Issue 2 , Pages 242-250 , August 2008

Association of Arachidonate 12-Lipoxygenase Genotype Variation and Glycemic Control With Albuminuria in Type 2 Diabetes

  • Yongmei Liu, MD, PhD

      Affiliations

    • Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC
    • Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
    • Corresponding Author InformationAddress correspondence to Yongmei Liu, MD, PhD, Department of Epidemiology, Division of Public Health Sciences, Medical Center Blvd, Winston-Salem, NC 27157.
    • ,
  • Barry I. Freedman, MD

      Affiliations

    • Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • Kathryn P. Burdon, PhD

      Affiliations

    • Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC
    • Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • Carl D. Langefeld, PhD

      Affiliations

    • Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • Timothy Howard, PhD

      Affiliations

    • Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • David Herrington, MD, MHS

      Affiliations

    • Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • David C. Goff Jr, MD, PhD

      Affiliations

    • Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC
    • Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • Donald W. Bowden, PhD

      Affiliations

    • Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
    • Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC
    • Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • Lynne E. Wagenknecht, DrPH

      Affiliations

    • Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • Catherine C. Hedrick, PhD

      Affiliations

    • Department of Medicine and Cardiovascular Research Center, University of Virginia, Charlottesville, VA.
    • ,
  • Stephen S. Rich, PhD

      Affiliations

    • Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC

Received 15 August 2007 ,Accepted 5 December 2007.

References 

  1. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426
  2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–389
  4. DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289–1298
  5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405–412
  6. American Association of Clinical Endocrinologists. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract. 2002;8(suppl 1):S5–S11
  7. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med. 1999;16:716–730
  8. Barnett AH. Treating to goal: Challenges of current management. Eur J Endocrinol. 2004;151(suppl 2):T3–T7
  9. Ma J, Natarajan R, LaPage J, et al. 12/15-Lipoxygenase inhibitors in diabetic nephropathy in the rat. Prostaglandins Leukot Essent Fatty Acids. 2005;72:13–20
  10. Langefeld CD, Beck SR, Bowden DW, et al. Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. Am J Kidney Dis. 2004;43:796–800
  11. Kasinath BS. Lipoxygenases in renal injury—Loading the matrix. Kidney Int. 2003;64:1918–1919
  12. Kim YS, Reddy MA, Lanting L, et al. Differential behavior of mesangial cells derived from 12/15-lipoxygenase knockout mice relative to control mice. Kidney Int. 2003;64:1702–1714
  13. Kang SW, Adler SG, Nast CC, et al. 12-Lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney Int. 2001;59:1354–1362
  14. Kang SW, Natarajan R, Shahed A, et al. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol. 2003;14:3178–3187
  15. Reddy MA, Adler SG, Kim YS, et al. Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol. 2002;283:F985–F994
  16. Antonipillai I, Nadler J, Vu EJ, et al. A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab. 1996;81:1940–1945
  17. Fridman C, Ojopi EP, Gregorio SP, et al. Association of a new polymorphism in ALOX12 gene with bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2003;253:40–43
  18. Carlson CS, Eberle MA, Rieder MJ, et al. Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat Genet. 2003;33:518–521
  19. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics. 1995;29:311–322
  20. O'Connell JR. Zero-recombinant haplotyping: Applications to fine mapping using SNPs. Genet Epidemiol. 2000;19(suppl 1):S64–S70
  21. Analysis of Messy Data, vol I: Designed Experiments. New York, NY: Van Nostrand Reinhold; 1984;
  22. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225–2229
  23. Warram JH, Gearin G, Laffel L, et al. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996;7:930–937
  24. Reilly KB, Srinivasan S, Hatley ME, et al. 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem. 2004;279:9440–9450
  25. Gillmor SA, Villasenor A, Fletterick R, et al. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat Struct Biol. 1997;4:1003–1009
  26. Guo Y, Zhang X, Tan W, et al. Platelet 12-lipoxygenase Arg261Gln polymorphism: Functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms. Pharmacogenet Genomics. 2007;17:197–205
  27. SeattleSNPs Programs for Genomic Applications: ALOX12:arachidonate 12-lipoxygenase. http://pga.gs.washington.edu/data/alox12/Accessed September 20, 2007
  28. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285–2293
  29. Davidson JA. Treatment of the patient with diabetes: Importance of maintaining target HbA(1c) levels. Curr Med Res Opin. 2004;20:1919–1927
  30. American Diabetes Association. Clinical practice recommendations 2000. Diabetes Care. 2000;23(suppl 1):S1–S116

 Originally published online as doi:10.1053/j.ajkd.2007.12.033 on March 24, 2008.

PII: S0272-6386(08)00067-X

doi: 10.1053/j.ajkd.2007.12.033

American Journal of Kidney Diseases
Volume 52, Issue 2 , Pages 242-250 , August 2008

Article Tools

* Image Usage & Resolution